已收盘 08-01 16:00:00 美东时间
0.000
0.00%
Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") is today reminding shareholders of the key dates associated with its upcoming 25% Preferred stock dividend.Shareholders of record on July
07-18 21:37
Nutriband Inc. is informing shareholders about upcoming key dates for its 25% Preferred stock dividend. Shareholders of record on July 25, 2025, will receive one preferred share for every four common shares held, with the payout on August 5. Each preferred share is convertible to one common share upon FDA approval of the company's AVERSA Fentanyl product, which uses abuse-deterrent transdermal technology. If unconverted, preferred shares will ear...
07-18 13:15
Nutriband Inc. announced a 25% preferred stock dividend, with eligible shareholders receiving one preferred share for every four common shares held, based on July 25, 2025 records, payable on August 5. Each preferred share is convertible into one common share upon FDA approval of their AVERSA fentanyl product. If unconverted, preferred shares will receive annual cash dividends. The company focuses on developing abuse-deterrent fentanyl patches us...
07-02 12:05
Nutriband and Kindeva have completed commercial manufacturing process scale-up for its lead product Aversa™ Fentanyl, an abuse-deterrent fentanyl patchNutriband is partnering with Kindeva to develop Aversa™
06-18 19:01
Nutriband Inc. announces the issuance of U.S. Patent No. 12,318,492 for its AVERSA™ abuse-deterrent transdermal technology, expanding its intellectual property protection in the U.S. This technology, which prevents drug abuse, misuse, and diversion, is already patented in 46 countries, including the U.S., Europe, Japan, China, and Australia. Nutriband's lead product, Aversa™ Fentanyl, an abuse-deterrent pain patch, has the potential to generate $...
06-09 11:30
Nutriband Inc. CEO Gareth Sheridan will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on June 5th at 4PM EST. The event includes a fireside Q&A and 1x1 investor meetings. The live presentation and archived webcast will be available on the company's website and Channelchek. Nutriband focuses on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch using AVERSA™ t...
06-03 12:00
Nutriband Inc. reported Q1 2025 revenue of $667,000, up 63% YOY, driven by expansion of kinesiology tape production via Pocono Pharma. The company secured partnerships with major retailers like Target and Walmart. Additionally, Nutriband finalized a product development partnership with Kindeva Drug Delivery to advance AVERSA Fentanyl, the first abuse-deterrent opioid patch, targeting peak US sales of $80-$200 million annually.
06-02 12:00
Shares of Nutriband Inc. (NASDAQ:NTRBW – Get Rating) rose 1% on Thursday . The ...
2023-03-24 14:43
Nutriband Inc. (NASDAQ:NTRBW – Get Rating) rose 16% during mid-day trading on M...
2023-02-07 15:24
Nutriband Inc. (NASDAQ:NTRBW – Get Rating) shares traded down 20.4% during trad...
2023-01-14 15:01